Stay up to date with the latest research and clinical updates on kidney cancer from the 2025 American Society of Clinical Oncology Annual Meeting.
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
68Ga-NY104 detected using PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with mccRCC.
Updated phase 3 study assesses long-term outcomes of adjuvant pembrolizumab in patients with ccRCC at risk of recurrence.
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Pathologic response and IHC post-treatment influx of CD8+CD39+ TILs are linked with prolonged DFS after neoadjuvant therapy.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on KEYNOTE-564, NEOAVAX, and more.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.